RA123 / Sanofi - LARVOL DELTA

RA123, a new GLS1 allosteric inhibitor demonstrates in vitro and in vivo activity in multiple myeloma models (AACR 2023) - "In conclusion, this study demonstrated that RA123, a new specific GLS1 allosteric inhibitor was able to impact multiple myeloma tumor cell growth both in vitro and in vivo. This effect was associated with reduced glutamate pools and accumulation of glutamine levels within the tumor cells."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • GLS1